Physician profile
Robert H Rivera
NPI 1659447977
$2,323.86
in general payments reported to CMS, 2019-2025
22 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $142 · 2022: $20.87 · 2023: $192 · 2024: $489 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.80 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $322.54 | 2019 | |
| Abbvie INC. | $214.08 | 2023-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $164.35 | 2023-2024 | |
| Ardelyx, INC. | $152.21 | 2024-2025 | Ibsrela |
| Radius Health, INC. | $151.22 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $147.01 | 2024-2025 | Breztri, Farxiga |
| Allergan, INC. | $127.87 | 2020 | |
| Boston Scientific Corporation | $124.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.71 | 2019 | |
| Astellas Pharma US INC | $75.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.05 | 2019 | |
| Merck Sharp & Dohme LLC | $33.65 | 2019 | |
| Gilead Sciences, INC. | $28.78 | 2025 | |
| Aurinia Pharma U.S., INC. | $26.82 | 2024 | Lupkynis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.98 | 2024 | Zepbound |
| Novartis Pharmaceuticals Corporation | $24.24 | 2019 | |
| Pfizer INC. | $23.04 | 2025 | |
| Esperion Therapeutics, INC. | $21.91 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $21.54 | 2025 | Austedo Xr |
| Ironwood Pharmaceuticals, INC | $21.25 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.